No Data Yet
The U.S. Securities and Exchange Commission has stopped the approval of exchange-traded funds offering more than 2x daily leverage, citing non-compliance with derivatives regulations. This impacts product issuers and signals a stricter stance on complex retail-focused products.
Alnylam Pharmaceuticals (ALNY) will be added to the Nasdaq-100 Index on December 22, 2025. This significant event provides a strong institutional buying catalyst, directly countering recent market concerns about near-term growth headwinds and a lack of late-stage pipeline news.
Brookfield Corporation has priced a C$1 billion medium-term note offering. The move is a strategic refinancing measure to redeem existing, higher-interest debt maturing in 2026, signaling prudent financial management rather than a new capital raise.
Markets saw significant single-stock volatility on December 12, with the biotech sector shaken by a major clinical trial failure at Rezolute. The semiconductor sector also faced broad pressure following a weak outlook from Broadcom, fueling concerns over high valuations in AI-related stocks.